Publikatielijst wa de boer (artikelen in peer reviewed journals)

PUBLIKATIELIJST WA de Boer (artikelen in peer reviewed journals)

de Boer WA. Hoofdpijn na lumbale punctie. Nederlands Tijdschrift voor Geneeskunde 1987; 131: 2009-
2012.
de Boer WA. Hoofdpijn na lumbale punctie. (brief)
Nederlands Tijdschrift voor Geneeskunde 1988; 132: 178-180.
de Boer WA, Klaassen CHL, Kunst MW. Pleuroperitoneale shunt ter behandeling van pleuritis
carcinomatosa exsudativa. Nederland Tijdschrift voor Geneeskunde 1988;132:1549.
de Boer WA. Dural trauma during lumbar puncture. (letter)
Archives of Internal Medicine 1989; 149:2139.
de Boer WA. Bed rest after lumbar puncture is obsolete. (letter) Anaesthesia 1989; 44: 934.
de Boer WA, Danner SA. HIV infection and squamous cell carcinoma of the sun exposed skin. AIDS
1990;4:91.
de Boer WA, Klaassen CHL, Huisman JW. D-Dimer latex assay as screening method in suspected deep
venous thrombosis of the leg. A clinical study and review of the literature.
Netherlands Journal of Medicine 1991;38:65-69
de Boer WA, Koolen MGJ, Roos CM, ten Cate JW. Tranexamic acid treatment of hemothorax in two
patients with malignant mesothelioma. Chest 1991;100:847-848.
Vos PE, de Boer WA, Wurzer JAL, van Gijn J. Subdural hematoma after lumbar puncture: two case
reports and review of the literature. Clinical Neurology and Neurosurgery 1991:93:127-132.
de Boer WA, Coevorden van F, Wiersinga WM. A rare case of Riedel's thyroiditis, 6 years after
retroperitoneal fibrosis. Two diseases with one pathogenesis? Netherlands Journal of Medicine
1992;40:190-196.
de Boer WA, Tytgat GNJ. A patient with osteomalacia as single presenting symptom of gluten sensitive
enteropathy. Journal of Internal Medicine 1992;232:81-85.
de Boer WA, Tytgat GNJ. Disappearance of mesenteric lymphadenopathy with gluten free diet in celiac
sprue. Journal of Clinical Gastroenterology 1993: 16: 317-319.
de Boer WA. Riedel's thyroiditis, retroperitoneal fibrosis and sclerosing cholangitis: diseases with one
pathogenesis? (letter) Gut 1993;34:714.
de Boer WA. Helicobacter Pylori, van commensaal tot pathogeen. Nederlands Militair Geneeskundig
Tijdschrift 1993;46:118-121.
de Boer WA, Tytgat GNJ. Review article : drug therapy for reflux oesophagitis. Alimentary Pharmacology
and Therapeutics 1994;8:147-157.
de Boer WA, Driessen WMM, Potters HVPJ, Tytgat GNJ. Randomized study comparing 1 with 2 weeks
of quadruple therapy for eradicating Helicobacter pylori. American Journal of Gastroenterology
1994;89:1993-1997.
de Boer WA. Treatment for Helicobacter pylori infection. (letter) Journal of Clinical Gastroenterology
1994;19:347-350.
Kooman JP, de Boer WA. Volumetherapie bij patienten met een hypovolemische shock. Nederlands
Militair Geneeskundig Tijdschrift 1994;47:125-130.
Dierkx RIJ, de Boer WA. Coeliakie: nieuwe ontwikkelingen in diagnostiek en screening. Nederlands
Militair Geneeskundig Tijdschrift 1994;47:184-188.

de Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Effect of acid suppression on efficacy of treatment
for Helicobacter pylori infection. Lancet 1995;345:817-20.
de Boer WA, Tytgat GNJ. Helicobacter pylori eradication and reinfection. (letter) Lancet 1995;345:1646-
1648.
de Boer WA, F van Haren, Driessen WMM. Marking clips, a new method for the accurate positioning of
self-expandable oesophageal stents. Gastrointestinal Endoscopy 1995;42:73-6.
de Boer WA, Tytgat GNJ. Review article: the best therapy for Helicobacter pylori infection. Should
efficacy or side effect profile determine our choice? Scandinavian Journal of Gastroenterology
1995;30:401-407.
de Boer WA, Driessen WMM. Treatment of Helicobacter pylori infection. (letter) Archives of Internal
Medicine 1995;155:330-331.
de Boer WA. Helicobacter pylori eradication. (letter) Alimentary Pharmacology & Therapeutics
1995;9:85-6.
Vos RJ, de Boer WA, Haas FDB. Is there a relationship between psoriasis and coeliac disease? Journal
of Internal Medicine 1995;237:118.
de Boer WA, Tytgat GNJ. Ninety percent cure; which anti-Helicobacter treatment can achieve this
treatment goal? (editorial) American Journal of Gastroenterology 1995;90:1381-2.
de Boer WA. [13 C] urea breath test. (letter) American Journal of Gastroenterology 1995;90:2069-70.
de Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Quadruple therapy compared with dual therapy for
eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre
study. European Journal of Gastroenterology & Hepatology 1995;7:1189-94.
Van de Wouw BAM, de Boer WA, Jansz AR, Staals APG, Roymans RTJM. Serodiagnosis of
Helicobacter pylori infection: an evaluation of a commercially available ELISA-IgG. Netherlands Journal of
Medicine 1995;47:272-277.
de Boer WA, Driessen WMM. Resolution of gastric outlet obstruction after eradication of Helicobacter
pylori. Journal of Clinical Gastroenterology 1995;21:329-330.
de Boer WA, Driessen WMM, Tytgat GNJ. Only four days of quadruple therapy can effectively cure
Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 1995;9:633-8
van de Wouw BAM, de Boer WA, Jansz AR, Roymans RTJM, Staals APG. Comparison of three
commercially available enzyme linked immunosorbent assays and biopsy dependent diagnosis for detec-
ting Helicobacter pylori infection. Journal of Clinical Microbiology 1996;34:94-7
Lai JYL, de Boer WA, Driessen WMM, Geuskens LM. Long-term follow-up after cure of Helicobacter
pylori infection with 4-days of quadruple therapy. Aliment Pharmacol Ther 1996;10:645-50.
de Boer WA, van Etten RJXM, Lai JYL, Schneeberger PM, van de Wouw BAM, Driessen WMM.
Effectiveness of 7 day quadruple therapy using lansoprazole instead of omeprazole in curing
Helicobacter pylori infection. Helicobacter 1996;1:145-150.
de Boer WA, van Etten RJXM, Schade RWB, Ouwehand ME, Schneeberger PM, Tytgat GNJ. Four day
lansoprazole-quadruple therapy is very effective in curing Helicobacter pylori infection. American Journal
of Gastroenterology 1996;91:1778-82.
de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A
personal viewpoint. Journal of Clinical Gastroenterology 1996;22:313-16.
de Boer WA, Tytgat GNJ. How to treat Helicobacter pylori infection - Should treatment strategies be
based on testing bacterial susceptibility? A personal viewpoint. European Journal of Gastroenterology &
Hepatology 1996;8:709-16.
de Boer WA. Helicobacter pylori en peptische ulcera. Bijblijven 1996;12:13-20.
de Boer WA, van Zwet TA. Diagnose and treat Helicobacter pylori as any other infectious disease.
(letter) American Journal of Gastroenterology 1996;91:2255-6.
de Boer WA, van Etten RJXM, Schade RWB, Ouwehand ME, Schneeberger PM, van Unnik AJM, Tytgat
GNJ. One-day intensified lan-soprazole-quadruple therapy for cure of Helicobacter pylori infection.
Alimentary Pharmacology Therapeutics 1997;11:109-12
de Boer WA. Perforated duodenal ulcer. (letter) New England Journal of Medicine 1997;337:1013.
de Boer WA. Diagnosis of Helicobacter pylori infection. Review of diagnostic techniques and
recommendations for their use in different clinical settings. Scandinavian Journal of Gastroenterology
1997;32(suppl 223):35-42
van de Wouw BAM, de Boer WA, Hermsen HWEM, Valkenburg JGM, Geuskens LM. Usefulness of the
14C urea breath test as a semi-quantative monitoring instrument after therapy for Helicobacter pylori
infection. Scandinavian Journal of Gastroenterology 1997;32:112-7.
van Doorn LJ, Quint W, Schneeberger P, Tytgat GNJ, de Boer WA. The only good Helicobacter is a
dead Helicobacter. (letter) Lancet 1997;350:71-72.

de Boer WA. Gastric outlet obstruction and Helicobacter pylori. (letter) American Journal of
Gastroenterology 1997;92:362.
de Boer WA. Helicobacter pylori and non-ulcer dyspepsia. (letter) Scandinavian Journal of
Gastroenterology 1997;32:1183-4.
de Boer WA. Helicobacter pylori in de huisartsenpraktijk (1). Wie moet er worden behandeld? Tijdschrift
voor Huisarts Geneeskunde 1997;14:238-241.
de Boer WA. Helicobacter pylori in de huisartsenpraktijk (2). Hoe te behandelen. Tijdschrift voor Huisarts
Geneeskunde 1997;14:276-282.
Mahler T, van Caillie-Bertrand M, Bosmans JLM, de Boer WA. Helicobacter pylori bij kinderen. Patient
Care 1997;24:21-27.
Kuipers EJ, Kusters JG, de Boer WA. Current therapies of Helicobacter pylori infection. Bailliere Clin
Infect Dis 1997;4:395-412.
de Boer WA, van Etten RJXM, Schneeberger PM. Four-day lansoprazole-quadruple therapy in the
routine treatment of Helicobacter pylori infection. Netherlands Journal of Medicine 1998;52:10-15.
de Boer WA, van Etten RJXM, Coremans A, Schneeberger PM. Two-day "weekend" lansoprazole-
quadruple therapy for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 1998;12:77-
81.
de Boer WA, Haeck PWE, Otten MH, Mulder CJJ. Optimal treatment of Helicobacter pylori with ranitidine
bismuth citrate (RBC): A randomized comparison between two 7-day triple therapies and a 14-day dual
therapy. American Journal of Gastroenterology 1998;93:1101-7.
van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W en Quint W. Clinical
relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 1998;115:58-66.
Lahey RJF, Jansen JBMJ, de Boer WA, Verbeek ALM. Monitoring Helicobacter pylori eradication
therapy. (letter) American Journal of Gastroenterology 1998;93:844-5.

de Boer WA. Duodenal stenosis does regress after eradication of Helicobacter pylori! (letter) Journal of
Clinical Gastroenterology 1998;26:357-8.
de Boer WA. Quadruple therapy: first or second line anti-Helicobacter pylori therapy? in Galmiche JP,
Domschke WW eds. The treatment of gastro-oesophageal Reflux disease and Helicobacter pylori
infection. Research and Clinical Forums 1998;20:43-7.
van Doorn LJ, Figueiredo C, Megraud F, Pena S, Midolo P, Queiroz DMM, Carneiro F, van der Borght B,
Pegado MGF, Sanna R, de Boer WA, Schneeberger PM, Correa P, Ng EKW, Atherton J, Blaser MJ,
Quint WGV. Geographic distribution of VacA allelic types of Helicobacter pylori. Gastroenterology
1999;116:823-30.
de Boer WA, Joosen EAM. Disease management in ulcer disease. Scandinavian Journal of
Gastroenterology 1999;34 (suppl 230): 23-8.
Lai JYL, de Grauw WJC, de Boer WA. Helicobacter treatment with quadruple therapy in primary health
care for patients with a history of ulcer disease. Family practice 1999;16:483-8.
de Boer WA. Leading article: "Bismuth triple therapy: still a very important drug regimen for curing
Helicobacter pylori infection." European Journal of Gastroenterology and Hepatology 1999;11:697-700.
de Boer WA, Lerang F. Serology for follow-up of Helicobacter therapy. European Journal of General
Practice 1999;5:162.
de Boer WA, Tytgat GNJ. Clinical review. Treatment of Helicobacter pylori infection. British Medical
Journal 2000;320:31-4.
de Boer WA, van Etten RJXM, van de Wouw BAM, Schneeberger PM, van Oijen AHAM, Jansen JBMJ.
Bismuth based quadruple therapy for Helicobacter pylori. A single triple capsule plus Lansoprazole.
Alimentary Pharmacology & Therapeutics 2000:14:85-89.
Joosen EAM, Reininga JHA, Manders JMW, ten Ham JC, de Boer WA. Costs and benefits of a test-and-
treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice.
European Journal of Gastroenterology Hepatology 2000;12:319-25.
de Boer WA, van Etten RJXM, Schneeberger PM, Tytgat GNJ. A single drug for Helicobacter pylori
infection: First results with a new bismuth triple monocapsule. American Journal of Gastroenterology
2000:95:641-5.
van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WGV, de Boer WA. Importance of
Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000;46:321-6.
van Oijen AHAM, Verbeek AL, Jansen JBMJ, de Boer WA. Review article: treatment of Helicobacter
pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Alimentary
Pharmacology & Therapeutics 2000;14:991-999.
Lahey RJF, de Boer WA, Jansen JBMJ, van Lier HJJ, Schneeberger PM, Verbeek ALM. Diagnostic
performance of biopsy-based methods for determination of Helicobacter pylori infection without a
reference standard. Journal of Clinical Epidemiology 2000;53:742-6.
de Boer WA, de Laat L, Megraud F. Diagnosis of Helicobacter pylori infection. Current Opinion in
Gastroenterology 2000;16 (suppl 1):S5-S10.
de Boer WA, Borody TJ. Treatment failures and secondary resistance to antibiotics. A growing concern
in Helicobacter pylori therapy. (Commentary) Digestive & Liver Diseases 2000:32:673-5.
de Boer WA. Topics in Helicobacter pylori infection. Focus on a "search & treat" strategy for ulcer
disease. Highlights of Gastroenterology in the Netherlands 1999. Scandinavian Journal of
Gastroenterology 2000;35 suppl 232:4-9.

Janssen MJR, van Oijen AHAM, Verbeek ALM, Jansen JBMJ, de Boer WA. A systematic comparison of
triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth
citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Alimentary Pharmacology &
Therapeutics 2001;15:613-24.
Figueiredo C, Quint W, Nouhan N, van den Munckhof H, Herbrink P, Scherpenisse J, de Boer W,
Schneeberger P, Perez-Perez G, Blaser MJ, van Doorn LJ. Assessment of Helicobacter pylori vacA and
cagA genotypes and host serological response. J Clin Microbiol 2001;39:1339-44.
de Boer WA, Tytgat GNJ. Occasional viewpoint: "Search & treat" strategy to eliminate Helicobacter pylori
associated ulcer disease. Gut 2001;48:567-570.
De Laat LE, de Boer WA. The CLO-test as a reference method for Helicobacter pylori infection. (Letter)
European Journal of Gastroenterology & Hepatology 2001;13:1269-70
De Boer WA. A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple
therapy monocapsule. Expert Opinion on Investigational Drugs 2001;10:1559-66.
De Boer WA, Tytgat GNJ. Should anti-Helicobacter therapy be different in patients with dyspepsia
compared with patients with peptic ulcer diathesis? European Journal of Gastroenterology & Hepatology
2001;13:1281-4.
Leheij RJF, van Rossum LGM, de Boer WA, Jansen JBMJ. Corpus gastritis in patients with endoscopic
diagnosis of reflux oesophagitis and Barrett’s oesophagus. Alimentary Pharmacology & Therapeutics
2002;16:887-891.
De Boer SY, van de Meeberg PC, Siem H, de Boer WA. Comparison of four-day and seven-day
pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection. The
Netherlands Journal of Medicine 2003;61:218-222.
O’Morain C, Borody T, Farley A, de Boer WA, Dallaire C, Schuman R, Piotrowski J, Fallone CA, Tytgat
GNJ, Megraud F, Spenard J. Efficacy and safety of single-triple capsules of bismuth biskalcitrate ,
metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an
international multicentre study. Alimentary Pharmacology & Therapeutics 2003;17:415-420.
Folmer H. de Wit NJ, Festen HPM, van Balen JAM, de Boer WA, Klinkenberg-Knol EC, Loffeld RJLF,
Numans ME. Landelijke transmurale afspraak Maagklachten. Huisarts Wet 2003;46:701-6.
Multidisciplinaire richtlijn maagklachten. Utrecht: Kwaliteitsinstituur voor de gezondheidszorg CBO. 2003.
(Lid van de werkgroep)
Kuipers EJ, Janssen MIJR, de Boer WA. Good bugs and bad bugs: indications and therapies for
Helicobacter pylori eradication. Current opinion in pharmacology 2003;3:480-5.
De Boer WA. Eradication therapy should be different for dyspeptic patients than for ulcer patients.
Canadian journal of gastroenterology 2003;17(suppl B):41B-45B
De Boer WA, Kuipers EJ, Kusters HG. Sequential therapy; a new treatment for Helicobacter pylori
infection. But is it ready for general use? Digestive and liver disease 2004;36:311-314.
De Boer WA, Kuipers EJ, Kusters HG. Sequential therapy for H. pylori: an “aberrant” therapy ready for
general use. Reply. (Letter) Digestive and liver disease 2004;36:852-6.
De Wit NJ, de Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GNJ, Smout AJPM. Treatment of
gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter
pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol ther 2004;20:451-8.
Janssen MJR, Laheij RJF, Jansen JBMJ, de Boer WA. The influence of pretreatment on cure rates of
Helicobacter pylori eradication. The Netherlands journal of Medicine 2004;62:192-6.

Talley NJ, Vakil N, Delaney B, Marshall B, Bytzer P, Engdtrand L, de Boer W, Jones R, Malfertheiner P,
Agreus L. Management issues in dyspepsia: Current consensus and cobntroversies. Scandinavian
Journal of Gastroenterology 2004;39:913-918
Van Ijzendoorn MC, Laheij RJF, de Boer WA, Jansen JBMJ. The importance of corpus biopsies for the
determination of Helicobacter pylori infection. The Netherlands Journal of Medicine 2005;63:141-5.
Janssen MJR, Laheij RJF, de Boer WA, Jansen JBMJ. Meta-analysis: the influence of pre-treatment with
a proton pump inhibitor on Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics
2005;21:341-5.
Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmmidt S, Schutze K et al. A randomized
comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis:
the EXPO study. (collaborator) Alimentary Pharmacology & Therapeutics 2005;21:739-746.
Janssen MJR, Schneeberger PM, de Boer WA, Laheij RJF, Jansen JBMJ. Lage prevalentie van
metronidazol en clarithromycineresistente Helicobacter pylori in de regio ’s Hertogenbosch, 1998-2003.
Nderlands Tijdschrift voor geneeskunde 2005;149:2175-7
De Wit NJ, van Barneveld TA, Festen HPM, Loffeld RJLF, van Pinxteren B, Numans ME namens dee
NHG-CBO werkgroep maagklachten (lid van de werkgroep). Richtlijn maagklachten. Nederlands
Tijdschrift voor Geneeskunde 2005;149:1386-92.
De Boer WA, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori
influence response rate or speed of symptom control in patients with gastroesophageal reflux disease
treated with rabeprazole? Scandinavian Journal of Gastroenterology 2006;41:1147-54
Van Keeken N, van Hattum E, de Boer WA. Validation of a new commercially available dry rapid urease
test for the diagnosis of Helicobacter pylori infection in gastric biopsies. Netherlands Journal of Medicine
2006;64:329-33.
(This article won the 2007 award for the best article published in the Netherlands Journal of Medicine in
2006: editorial board; Netherlands Journal of Medicine 2007;65:41)
van Kerkhoven LA, Laheij RJ, Aparicio N, de Boer WA, van den Hazel S, Tan AC, Witteman BJ, Jansen
JB. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-
controlled trial. Clin Gastroenterol Hepatol 2008;6:46-52
Schrauwen RWM, Janssen MJR, de Boer WA. Seven-day triple therapy with levofloxacin is very
effective for Helicobacter pylori eradication. The Netherlands Journal of Medicine 2009;67:96-101.
De Boer WA. Eerst de pH of eerst de Hp ? Overwegingen bij de herziene NHG standaard Maagklachten
Nederlands Tijdschrift voor Geneeskunde 2013;157:1028-9.
HOOFDSTUK IN BOEK
de Boer WA. Towards monotherapy - What progress? First results with a new "single triple" capsule. in
Hunt RH, Tytgat GNJ eds. Helicobacter pylori Basic mechanisms to clinical cure 1998. Chapter 46, page
456-461. Kluwer Academic publishers, Dordrecht, the Netherlands.
Kuipers EJ, de Boer WA, Ottow RT, Oostvogel HJM. Ulcera ventriculi en duodeni. In : van Lanschot JJB,
Gouma DJ, Schouten WR, Tytgat GNJ, Jansen PLM (eds). Gastrointestinale chirurgie en
gastroenterologie in onderling verband. Hoofdstuk 4; 62-80. Houten/Diegem, Bohn Stafleu van Loghum,
1999
de Boer WA. Quadruple therapy. Second- or first-line eradication regimen ? In : Scarpignato C, Bianchi
Porro G (eds). Clinical Pharmacology and Therapy of Helicobacter pylori infection. Progress in Basic and
Clinical Pharmacology. Basel, Karger, 1999, vol 11, 212-26.
de Boer WA. Strategies for therapy failures: Choice of "back-up"-regimen determined by primary
treatment for Helicobacter pylori infection. In Hunt RH, Tytgat GNJ eds. Helicobacter pylori Basic
Mechanisms to Clinical Cure 2000. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2000. p
609-21.
de Boer WA. Helicobacter pylori and dyspepsia strategies – debate: Yes - a test-and-treat strategy is a
viable option in primary care. In Hunt RH, Tytgat GNJ eds. Helicobacter pylori Basic Mechanisms to
Clinical Cure 2002. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2002. p283-295.
de Boer WA. Eradication therapy should be different for dyspeptic patients compared with ulcer patients.
In Hunt RH, Tytgat GNJ eds. Helicobacter pylori Basic Mechanisms to Clinical Cure 2002. Dordrecht, the
Netherlands: Kluwer Academic Publishers; 2002. p353-361.
de Boer WA, de Vos M. Gastric and duodenal ulcers. Hoofdstuk in textbook: “Integrated Medical and
surgical Gastroenterology”. Edited by van Lanschot JJB, gouma DJ, Jansen PLM, Jones EA, Pinedo Hm,
Schouten WR, Tytgat GNJ. Bohn Stafleu van loghum, Houten 2004.

ABSTRACTS
de Boer WA, Klaassen CHL, Huisman JW. D-Dimer latex assay as screening method in suspected deep
venous thrombosis of the leg. (abstract Nederlandse Internistendagen, Veldhoven, 27-28 april 1989.
Netherlands Journal of Medicine 1989;35:A29
de Boer WA, Driessen WMM. Randomized study comparing one with two weeks of triple therapy for
eradicating Helicobacter Pylori. (abstract najaarsvergadering Nederlandse Vereniging voor
Gastroenterologie, Veldhoven, 7-8 oktober 1993.) Netherlands Journal of Medicine 1994;44:A43.
de Boer WA, Driessen WMM. Randomized study comparing one with two weeks of triple therapy for
eradicating Helicobacter pylori. (abstract Internistendagen, Veldhoven, 28-29 april 1994) Neth J Med
1994;44:A87-A88.
de Boer WA, Driessen WMM. Randomized study comparing one with two weeks of triple therapy for
eradicating Helicobacter pylori. (abstract Digestive Disease Week, New Orleans, USA, 15-18 may 1994)
Gastroenterology 1994;106:A67.
de Boer WA, Wouw van de BAM, Driessen WMM, Jansz AR. Is Helicobacter pylori infection an
occupational hazard? A sera epidemiological study among endoscopists. (abstract voorjaarsvergadering
Nederlandse Vereniging voor Gastroenterologie, Veldhoven, 16-17 maart 1995) Netherlands Journal of
Medicine 1995;47:A18.
de Boer WA, Wouw van de BAM, Driessen WMM, Jansz AR. Is Helicobacter pylori infection an
occupational hazard? A sera epidemiological study among endoscopists. (abstract Internistendagen,
Veldhoven, 27-28 april 1995) Netherlands Journal of Medicine 1995;46:A73-A74.
de Boer WA, Driessen WMM. Dual therapy with omeprazole plus amoxicillin versus quadruple therapy
with omeprazole, bismuth, tetracycline and metronidazole for cure of H. pylori infection in ulcer patients.
Results of a randomised single-center study. (abstract Internistendagen, Veldhoven, 27-28 april 1995)
Netherlands Journal of Medicine 1995;46:A74.
Boer de WA, Driessen WMM. Quadruple therapy of omeprazole, bismuth, tetracycline plus metronidazole
versus dual therapy of omeprazole plus amoxicillin for cure of Helicobacter pylori infection in ulcer
patients. Results of a randomised single-center study. (abstract voorjaarsvergadering Nederlanse Ver-
eniging voor Gastroenterologie, Veldhoven, 16-17 maart 1995) Netherlands journal of Gastroenterology
1995;47:A20.
Boer de WA, Driessen WMM. Dual therapy of omeprazole plus amoxicillin versus quadruple therapy of
omeprazole, bismuth, tetracycline and metronidazole for cure of H. pylori infection in ulcer patients.
(abstract Digestive Disease Week, San Diego mei 1995) Gastroenterology 1995;108:A80.
Boer de WA, Driessen WMM. Omeprazole increases the efficacy of triple therapy. Results of a
randomised prospective study of triple therapy with or without omeprazole for the eradication of H. pylori.
(abstract Internistendagen, Veldhoven, 27-28 april 1995) Netherlands Journal of Medicine 1995;46:A75.
Boer de WA, Driessen WMM. Omeprazole increases the efficacy of triple therapy. results of a
randomised prospective study of triple therapy with or without omeprazole for the eradication of
Helicobacter pylori. (abstract najaarsvergadering Nederlandse Vereniging voor Gastroenterologie,
Veldhoven, 27-28 oktober 1994) Netherlands Journal of Medicine 1995;46:A2.
Boer de WA, Driessen WMM. Omeprazole increases the efficacy of triple therapy. Results of a
randomised prospective study of triple therapy with or without omeprazole for the eradication of H. pylori.
(abstract Digestive Disease Week, San Diego, mei 1995) Gastroenterology 1995;108:A80.
Boer de WA, Driessen WMM. Only four days of quadruple therapy can effectively cure Helicobacter pylori
infection. (abstract Digestive Disease Week, San Diego, mei 1995) Gastroenterology 1995;108:A80.
Boer de WA, Driessen WMM. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. (abstract najaarsvergadering Nederlanse Vereniging voor Gastroenterologie, Veldhoven, 5-6 oktober 1995) Netherlands Journal of Medicine 1996;48:A15. Hermsen HWEM, de Boer WA, Driessen WMM, Geuskens LM, van de Wouw BAM, Jansen JBMJ. Long-term follow-up after successful eradication of Helicobacter pylori with 1 or 2 weeks of quadruple therapy. (abstract najaarsvergadering Nederlandse Vereniging voor Gastroenterologie, Veldhoven, 5-6 oktober 1995) Netherlands Journal of Medicine 1996:48:A14-A15. van de Wouw BAM, de Boer WA, Jansz AR. Performance of three commercially available ELISA's in detecting Helicobacter pylori infection when compared to biopsy-dependent diagnosis. (abstract najaarsvergadering Nederlandse Vereniging voor Gastroenterologie, Veldhoven, 5-6 oktober 1995) Netherlands Journal of Medicine 1996;48:A13. van Doorn LJ, Kam AL, Schneeberger PM, Quint WGV, de Boer WA. Importance of cag A and vac A status for the efficacy of anti-Helicobacter treatment. (Abstract Netherlands Society of Gastroenterology, spring meeting, Veldhoven 20-21 march 1997) European Journal of Gastroenterology & Hepatology 1997;9:A16. Beker JA, Dekkers CMP, de Boer WA, Haeck PWE, Wetzels AMH. High cure-rates with ranitidine bismuth citrate (pylorid) plus clarithromycin given twice daily. (Abstract Netherlands Society of Gastroenterology, spring meeting, Veldhoven 20-21 march 1997) European Journal of Gastroenterology & Hepatology 1997;9:A18. de Boer WA, Haeck PWE, Mulder CJJ. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate: a randomised comparison between two 7 day triple therapies and a 14 day dual therapy. (Abstract Netherlands Society of Gastroenterology, autumn meeting, Veldhoven 2-3 october 1997) European Journal of Gastroenterology & Hepatology 1997;9:A44 de Boer WA, van Etten RJXM. Weekend Lansoprazole-quadruple therapy for Helicobacter pylori infection. (Abstract Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori, Lissabon 12-14 september 1997) Gut 1997;41(suppl 1):A97. de Boer WA, van Etten RJXM, Schneeberger PM. Four days lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori. (Abstract Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori, Lissabon 12-14 september 1997) Gut 1997;41 (suppl 1):A101. van Doorn LJ, Kam AL, Schneeberger PM, Quint WGV, de Boer WA. Het belang van de cag A en vac A status van Helicobacter pylori voor de effectiviteit van eradicatie therapie. (Voorjaarsvergadering Nederlandse Vereniging voor Medische Microbiologie, Lunteren 22-23 april 1997) Nederlands Tijdschrift voor Medische Microbiologie 1997;5 (suppl april):S30. de Boer WA. Therapie van Helicobacter pylori. Moet de therapiekeuze bepaald worden door het resistentie-spectrum? (Voorjaarsvergadering Nederlandse Vereniging voor Medische Microbiologie, Lunteren 22-23 april 1997) Nederlands Tijdschrift voor Medische Microbiologie 1997;5 (suppl april):S31. de Boer WA, Borody TJ. Towards monotherapy for Helicobacter pylori infection.: first results with a single triple capsule. (Abstract Digestive Disease Week, New Orleans, mei 1998) Gastroenterology 1998;114:A98. Figueiredo C, Quint W, Scneeberger P, de Boer WA, van Doorn LJ. Ice A1 is an independent Helicobacter pylori strain marker for peptic ulcer disease. (Abstract Digestive Disease Week, New Orleans, mei 1998.) Gastroenterology 1998;114:A121. Lahey RJF, de Boer WA, Janssen JBMJ, van Lier HJJ, Schneeberger ALM, Verbeek ALM. Diagnostic performance of biopsy-based methods for detection of Helicobacter pylori infection in routine clinical care. (Abstract Digestive Disease Week, New Orleans, mei 1998.) Gastroenterology 1998;114:A191. Joosen EAM, de Boer WA, Reininga JHA, Manders JMW, ten Ham JC. Costs and benefits of a test and treat strategy in H. pylori infected subjects: a prospective and controlled intervention study in general practice. (Abstract Spring meeting Dutch society of Gastroenterology & Hepatology, Veldhoven, maart 1999) van de Wouw BAM, Lahey RJF, Schneeberger PM, de Boer WA. IgG serology is a reliable predictor for cure of H. pylori infection. (Abstract Spring meeting Dutch society of Gastroenterology & Hepatology, Veldhoven, maart 1999) De Boer SY, van de Meeberg PC, Siem TH, de Boer WA. Comparison of seven and four day pantoprazole based quadruple therapy as a routine treatment for Helicobacter pylori infection. (abstract Internistendagen, Veldhoven, april 1999) Neth J Med 1999;54:A40-A41. van de Wouw BAM, Lahey RJF, Schneeberger PM, de Boer WA. IgG serology at 6 months is a reliable predictor for cure of H. pylori infection. (abstract DDW, Orlando may 1999) Gastroenterology 1999;116:A357. De Boer SY, van de Meeberg PC, Siem TH, de Boer WA. Comparison of seven and four day pantoprazole based quadruple therapy as a routine treatment for Helicobacter pylori infection. (abstract DDW, Orlando, may 1999) Gastroenterology 1999;116:A145. Joosen EAM, de Boer WA, Reininga JHA, Manders JMW, ten Ham JC. Costs and benefits of a test and treat strategy in H pylori infected subjects: a prospective and controlled intervention study in general practice. (Abstract DDW, Orlando may 1999) Gastroenterology 1999;116:A68) Janssen MJR, van Oijen AHAM, Janssen JBMJ, de Boer WA. Treatment of Helicobacter pylori infection with triple therapy regimens containing PPI/RBC plus clarithromycin and either amoxycillin or a nitro-imidazole: a systematic review. (Abstract najaarsvergadering Nederlanse Vereniging voor Gastroen-terologie, Veldhoven 5-6 oktober 2000) European Journal of Gastroenterology & Hepatology 2000;12:A49. Laheij RJ, de Boer WA, Jansen JBMJ, van Rossum LG, Verbeek AL. The effect of corpus gastritis healing on the occurrence of reflux oesophagitis. (Abstract DDW, San Diego, may 2000) Gastroenterology 2000;118:A1263. Jansen JBMJ, Laheij RJF, de Boer WA, van Rossum LGM. Corpus gastritis and the occurence of reflux oesophagitis and Barretts oesophagus. (Abstract UEGW, Brussel, November 2000) Gut 2000;47(suppl III):A70. Spenard A, O’Morain C, Buckley M, Borody TJ, Wettstein A, Farley A, de boer WA, Dal aire C, Tytgat GNJ. Brink MJ, Fallone CA, Piotrowslki J, Schuman R, Megraud F. International trial on a single triple capsule of bismuth subcitrate, metronidazole and tetracycline given with omeprazole in H. pylori eradication: preliminary results. (abstract 1978, UEGW, Amsterdam, oktober 2001). De Wit N, de Boer WA, Smout A, Geldof H, Hazelhoff B, Tytgat GNJ. Does Helicobacter pylori infection affect symptomatic response in GERD? Abstract DDW, San Francisco 19-22 mei 2002. Gastroenterology 2002;122:A198. De Boer WA, de Wit NJ, Smout AJPM, Geldof H, Hazelhoff B, Tytgat GNJ. Helicobacter pylori infection does not influence response rate or speed of symptom control in GERD patients treated with rabeprazole. (abstract 11.11, XV International Workshop on Gastrointestinal Pathology and Helicobacter, Athene, Griekenland 11-14 september 2002. Smout A, de Wit NJ, de Boer WA, Geldof H, Hazelhoff B, Tytgat GNJ. Helicobacter pylori infection does not alter symptomatic response to treatment with rabeprazole in GERD patients. (abstract Tue-G-486, UEGW, Geneve, 19-23 oktober 2002) Gut 2002;51 (suppl III):A214. De Boer WA, van Alfen C, Ryden J. Validation of a new portable near patient urea breath test; the Heliprobe system. Abstract XV th nternational workshop Gastrointestinal pathology & Helicobacter (European Helicobacter study group), Stockholm, 3-6 oktober 2003. Helicobacter 2003;8:479-480. Van Ijzendoorn MC, Laheij RJF, Jansen JBMJ, de Boer WA. What is the added value of corpus biopsies to antral biopsies for the determination of H. pylori status? (Abstract najaarsvergadering Nederlandse vereniging voor Gastroenterologie, oktober 2003). Eur J Gastroenterol Hepatol 2003;15:A11. De Boer WA, van Alfen C, Badrawi S, van Oijen AHAM, Jansen JBMJ, Ryden J. Validation of a new portable near patient urea breath test; the Heliprobe system. (Abstract najaarsvergadering Nederlandse vereniging voor Gastroenterologie, oktober 2003). Eur J Gastroenterol Hepatol 2003;15:A72. De Boer WA, Ouwehand ME, Vos AH, Gisbertz IAM, Janssen MJR. Seven-day therapy with esomeprazole, amoxicillin and levofloxacin is very effective for H. pylori eradication. (abstract voorjaarsvergadering Nederlandse vereniging voor gastroenterologie) Veldhoven 16-17 maart 2006 De Boer WA, Otten MH, Man A hing WKH. Use of VSL#3, a probiotic combination is associated with a lower frequency and severity of abdominal pain and improved Quality of life in Irritable Bowel Syndrome (IBS) : data from the VIP (VSL#3 in PDS) study, a Multi-centre, prospective observational study. Abstrract najaarsvergadering Nederlandse Vereniging voor Gastroenterologie, Veldhoven oktober 2011 OVERIGE PUBLICATIES Kox RJ, Dormans TPJ, Boer de WA. Chronische longembolie. Medisch Journaal 1993; 22: 33-36. Mook WNKA van, Boer WA de, Driessen WMM. Percutane endoscopische gastrostomie. (PEG) Een van de alternatieven bij langdurige enterale voeding. Medisch journaal 1993, 22, 140-145. Boer de WA. De behandeling van refluxziekte. Janssen Medisch- Wetenschappelijk Nieuws 1993, 8 (9, oktober), 288-292. Boer de WA. De rol van Helicobacter Pylori bij peptische ulcera. Janssen Medisch-Wetenschappelijk Nieuws 1994, 9 (1, januari), 9-13. Boer de WA. Ontstoppen: de gastro-enteroloog als loodgieter. (eerste ervaring met een "ULTRAFLEX" stent bij een patient met slokdarmcarcinoom) Medisch Journaal 1994, 23, 22-24. Boer de WA. Openen door uitroeien. (De behandeling van maaguitgangstenose met triple therapie) Medisch Journaal 1994, 23, 24-26. Boer de WA. Helicobacter pylori, klinische betekenis en diagnostiek. Analyse, tijdschrift voor medische analisten, 1994, 49, 206-209. Dierkx RIJ, Boer de WA. Resultaten van een jaar ervaring met de perendoscopische biopsietechniek voor het nemen van dunne darmslijmvliesbiopten. Medisch Journaal 1994, 23, 78-81 de Vos RJ, Boer de WA. Resultaten van een screeningsonderzoek op coeliakie bij psoriasis patienten. Medisch Journaal 1994, 23, 175-176. van Haren FMP, de Boer WA, Driessen WMM. Een nieuwe methode om selfexpandable stents in de slokdarm te positioneren. Medisch Journaal 1995;24:127-8. de Boer WA. Wat is het optimale beleid bij aangetoonde Helicobacter pylori in het maagslijmvlies? Internisten vademecum nummer 9, september 1996. de Boer WA. Helicobacter therapie in de Huisartsenpraktijk. Duo- triple of quadruple therapie? Janssen-Cilag Medisch Wetenschappelijk Nieuws 1997;12:4-10. de Boer WA. Helicobacter pylori in de huisartsenpraktijk (1). Wie moet er worden behandeld? Tijdschrift voor Huisartsgeneeskunde 1997;14:238-241. de Boer WA. Helicobacter pylori in de huisartsenpraktijk (2). Hoe te behandelen ? Tijdschrift voor Huisartsgeneeskunde 1997;14:276-282. de Boer WA. Behandeling van Helicobacter pylori infectie in 2000. een historisch perspectief. Medisch Journaal 2000;29:12-15. Janssen MJR, van Oijen AHAM, de Boer WA. Behandeling van Helicobacter pylori infectie in 2000. Modern Medicine 2000;860-866 de Boer WA. Maagklachten zijn goed te behandelen. In de Maagweek special van "Uw apotheker, Uw adviseur" Een brochure die van 13-17 november 2000 via apotheken aan patienten wordt uitgedeeld. de Boer WA. Bij welke titer in geval van positieve Helicobacter pylori serologie is er een indicatie voor (triple) therapie? Vademecum permanente nascholing huisartsen. 2003; jaargang 21, nr 19 (mei 2003) de Boer WA. De “Test & Treat” strategie bij patienten met maagklachten. Gastroactueel 2003; jaargang 7: nr 14 (december 2003) De Boer WA. De Maastricht consensus. Helicobacter pylori- richtlijnen in de praktijk. Magma (Tijdschrift van het Nederlands Genootschap van Maag-Darm-Leverartsen) 2004;10:6-7.

Source: http://www.bernhoven.nl/ZBH/Boer,_WA_de/Boer,_WA_de-Publicaties.pdf